| Autor: |
Mohsen Karami Fath, Kimiya Babakhaniyan, Mehran Anjomrooz, Mohammadrasoul Jalalifar, Seyed Danial Alizadeh, Zeinab Pourghasem, Parisa Abbasi Oshagh, Ali Azargoonjahromi, Faezeh Almasi, Hafza Zahira Manzoor, Bahman Khalesi, Navid Pourzardosht, Saeed Khalili, Zahra Payandeh |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Vaccines, Vol 10, Iss 9, p 1448 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2076-393X |
| DOI: |
10.3390/vaccines10091448 |
| Popis: |
Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
